Tirzepatide linked to lower weight in partial lipodystrophy
Median weight fell from 91.0 to 82.8 kg over a median 9.5 months in 40 people with the rare fat-storage disorder.
Limit: Dietary advice given alongside tirzepatide could also explain weight loss
Edited by Boris Djordjevic · AgingResearch.News
In a retrospective observational study, researchers reviewed records of 40 adults with partial lipodystrophy, a disorder involving missing or malfunctioning fat cells in parts of the body. All had diabetes; 35 were women, and median age was 47. Weekly tirzepatide injections usually started at 2.5 mg; the median dose was 7.5 mg, with median follow-up of 9.5 months.
Median results fell for a measure of longer-term blood sugar (65 to 52 mmol/mol) and blood fats called triglycerides (2.80 to 1.83 mmol/L). Median daily insulin requirements fell from 177.5 to 58.0 international units. Six participants (15%) stopped treatment: five because of digestive side effects and one after developing pancreatitis, inflammation of the pancreas. Three needed dose reductions, including one for low blood sugar. Among 28 with side-effect data, 46.4% reported nausea and 42.9% diarrhea. Diabetic eye disease worsened in four of 24 with follow-up screening; four improved.
Why it matters
Partial lipodystrophy involves severe insulin resistance—the body's poor response to insulin. With treatment options limited, the authors called for prospective studies, including evaluation earlier in the disorder.
Caveats
This small, single-center record review had no untreated comparison group, and participants also received dietary advice, so it cannot establish that tirzepatide caused the changes. It excluded children and people with generalized fat loss; side-effect records covered only 28 participants.
- Tirzepatide
- GLP-1 and incretin signaling
- Insulin/IGF-1 signaling
- Partial lipodystrophy
- Daily insulin requirement
- Humans
The paper
Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy
University of Cambridge
The Journal of Clinical Endocrinology and Metabolism, Mar 23, 2026, Open access
